血液透析患者对 Gam-COVID-Vac 疫苗产生的长期体液和细胞反应:前瞻性队列研究

IF 1 Q3 MEDICINE, GENERAL & INTERNAL
E.V. Parshina, Alexey Zulkarnaev, A. Tolkach, Andrey Ivanov, P. Kislyy
{"title":"血液透析患者对 Gam-COVID-Vac 疫苗产生的长期体液和细胞反应:前瞻性队列研究","authors":"E.V. Parshina, Alexey Zulkarnaev, A. Tolkach, Andrey Ivanov, P. Kislyy","doi":"10.29333/ejgm/14786","DOIUrl":null,"url":null,"abstract":"Purpose: The aim of this study is to assess long-term immunogenicity of the recombinant adenoviruses 26 and 5 vector-based COVID-19 vaccine Gam-COVID-Vac (Sputnik V, developed by N. F. Gamaleya National Research Centre, Russia) in patients receiving maintenance hemodialysis (HD) compared to healthy subjects.\nMaterials & methods: A prospective cohort study included patients treated with maintenance HD (n=23) and healthy volunteers (n=28). The levels of anti-severe acute respiratory syndrome coronavirus-2 specific IgG as well as specific T-cell responses were quantified in all participants at two time points: one and six months after complete vaccination. All participates were adults, had been vaccinated twice with Gam-COVID-Vac and had no prior history of confirmed COVID-19.\nResults: In both groups, IgG levels decreased from month one to six, however, antibodies did not decline more rapidly in HD group (analysis of variance p=0.7214 for the “time×group” interaction, non-adjusted model). At the end of the study, 48.0% of non-HD and 67.0% of HD participants showed T-cell positivity. T-spot counts dropped over time in non-HD controls, but not in HD subjects (p=0.0080 and p=0.1800, respectively).\nConclusions: Patients receiving HD maintain significant long-term humoral response after Gam-COVID-Vac vaccination, which is comparable to that in subjects with normal kidney function. Cellular response turned up to be more sustained over time in HD group.","PeriodicalId":44930,"journal":{"name":"Electronic Journal of General Medicine","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term humoral and cellular responses elicited by Gam-COVID-Vac vaccine in hemodialysis patients: A prospective cohort study\",\"authors\":\"E.V. Parshina, Alexey Zulkarnaev, A. Tolkach, Andrey Ivanov, P. Kislyy\",\"doi\":\"10.29333/ejgm/14786\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: The aim of this study is to assess long-term immunogenicity of the recombinant adenoviruses 26 and 5 vector-based COVID-19 vaccine Gam-COVID-Vac (Sputnik V, developed by N. F. Gamaleya National Research Centre, Russia) in patients receiving maintenance hemodialysis (HD) compared to healthy subjects.\\nMaterials & methods: A prospective cohort study included patients treated with maintenance HD (n=23) and healthy volunteers (n=28). The levels of anti-severe acute respiratory syndrome coronavirus-2 specific IgG as well as specific T-cell responses were quantified in all participants at two time points: one and six months after complete vaccination. All participates were adults, had been vaccinated twice with Gam-COVID-Vac and had no prior history of confirmed COVID-19.\\nResults: In both groups, IgG levels decreased from month one to six, however, antibodies did not decline more rapidly in HD group (analysis of variance p=0.7214 for the “time×group” interaction, non-adjusted model). At the end of the study, 48.0% of non-HD and 67.0% of HD participants showed T-cell positivity. T-spot counts dropped over time in non-HD controls, but not in HD subjects (p=0.0080 and p=0.1800, respectively).\\nConclusions: Patients receiving HD maintain significant long-term humoral response after Gam-COVID-Vac vaccination, which is comparable to that in subjects with normal kidney function. Cellular response turned up to be more sustained over time in HD group.\",\"PeriodicalId\":44930,\"journal\":{\"name\":\"Electronic Journal of General Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2024-07-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Electronic Journal of General Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29333/ejgm/14786\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Electronic Journal of General Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29333/ejgm/14786","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究旨在评估基于重组腺病毒 26 和 5 载体的 COVID-19 疫苗 Gam-COVID-Vac (Sputnik V,由俄罗斯 N. F. Gamaleya 国家研究中心开发)在接受维持性血液透析(HD)的患者中与健康受试者相比的长期免疫原性:前瞻性队列研究包括接受维持性血液透析治疗的患者(23 人)和健康志愿者(28 人)。所有参与者的抗严重急性呼吸系统综合征冠状病毒-2 特异性 IgG 和特异性 T 细胞反应水平在两个时间点进行了量化:完全接种疫苗后的 1 个月和 6 个月。所有参与者均为成年人,接种过两次 Gam-COVID-Vac 疫苗,且之前没有确诊过 COVID-19 的病史:结果:两组的 IgG 水平从第 1 个月到第 6 个月都有所下降,但 HD 组的抗体下降速度并没有更快("时间×组 "交互作用的方差分析 p=0.7214,非调整模型)。研究结束时,48.0% 的非 HD 参与者和 67.0% 的 HD 参与者显示出 T 细胞阳性。随着时间的推移,非 HD 对照组的 T 点计数下降,但 HD 受试者的 T 点计数没有下降(分别为 p=0.0080 和 p=0.1800):结论:接种 Gam-COVID-Vac 疫苗后,接受 HD 治疗的患者长期保持明显的体液反应,与肾功能正常的受试者相当。血液透析组的细胞反应更持久。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Long-term humoral and cellular responses elicited by Gam-COVID-Vac vaccine in hemodialysis patients: A prospective cohort study
Purpose: The aim of this study is to assess long-term immunogenicity of the recombinant adenoviruses 26 and 5 vector-based COVID-19 vaccine Gam-COVID-Vac (Sputnik V, developed by N. F. Gamaleya National Research Centre, Russia) in patients receiving maintenance hemodialysis (HD) compared to healthy subjects. Materials & methods: A prospective cohort study included patients treated with maintenance HD (n=23) and healthy volunteers (n=28). The levels of anti-severe acute respiratory syndrome coronavirus-2 specific IgG as well as specific T-cell responses were quantified in all participants at two time points: one and six months after complete vaccination. All participates were adults, had been vaccinated twice with Gam-COVID-Vac and had no prior history of confirmed COVID-19. Results: In both groups, IgG levels decreased from month one to six, however, antibodies did not decline more rapidly in HD group (analysis of variance p=0.7214 for the “time×group” interaction, non-adjusted model). At the end of the study, 48.0% of non-HD and 67.0% of HD participants showed T-cell positivity. T-spot counts dropped over time in non-HD controls, but not in HD subjects (p=0.0080 and p=0.1800, respectively). Conclusions: Patients receiving HD maintain significant long-term humoral response after Gam-COVID-Vac vaccination, which is comparable to that in subjects with normal kidney function. Cellular response turned up to be more sustained over time in HD group.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Electronic Journal of General Medicine
Electronic Journal of General Medicine MEDICINE, GENERAL & INTERNAL-
CiteScore
3.60
自引率
4.80%
发文量
79
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信